Department of Oncology & Hematology, Humanitas Clinical & Research Center, Via Manzoni 56, 20089 Rozzano (MI), Italy.
Polo Scienze Oncologiche ed Ematologiche, UOC di Oncologia Medica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli - Largo Francesco Vito 1, 00168 Rome, Italy.
Future Oncol. 2018 Apr;14(10):919-926. doi: 10.2217/fon-2017-0499. Epub 2018 Mar 12.
To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status.
PATIENTS & METHODS: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm/m for women and ≤55 cm/m for men, and nonsarcopenic patients.
Sarcopenia does not affect response to gefitinib treatment in EGFR mutated NSCLC patients, even if it is a bad prognostic indicator for overall survival (p = 0.035).
Early recognition of sarcopenia is beneficial for prevention of cancer cachexia and detection of patients at potential risk of serious adverse events. Gefitinib dosage should be reduced and modulated in sarcopenic patients.
评估存在 EGFR 突变的非小细胞肺癌（NSCLC）患者的 EGFR 突变状态与其肌肉减少症状态对吉非替尼疗效的影响。
我们回顾性评估了 33 例晚期 NSCLC 合并 EGFR 突变（外显子 19 或 21）的患者，根据其骨骼肌指数将其分为肌肉减少症患者（女性骨骼肌指数≤39cm/m，男性骨骼肌指数≤55cm/m）和非肌肉减少症患者。
肌肉减少症并不影响 EGFR 突变型 NSCLC 患者对吉非替尼治疗的反应，尽管它是总生存期的不良预后指标（p=0.035）。
早期识别肌肉减少症有利于预防癌症恶病质和发现有严重不良事件潜在风险的患者。应减少和调整肌肉减少症患者的吉非替尼剂量。
